PBYI Puma Biotechnology Inc

+0.54  (+3%)
Previous Close 15.63
Open 15.77
Price To Book 14.31
Market Cap 624363268
Shares 38,612,447
Volume 711,166
Short Ratio
Av. Daily Volume 1,071,871

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released at ASCO June 3, 2017.
HER2-positive metastatic breast cancer patients with brain metastases
Phase 2 biomarker data released December 7, 2016.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 additional data due 2H 2019.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 additional data due at ASCO June 2, 2019, 8am CT.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 3 data released December 17, 2018. PFS endpoint met but OS co-primary missed. Data to be presented at ASCO June 4, 2019, 10:09am CT. NDA filing summer 2019.
Neratinib - NALA
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
Approval announced July 17, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.
Neratinib (NERLYNX)
Extended adjuvant HER2-positive early stage breast cancer
Phase 1/2 interim data presented at ASCO June 2018. 9 PRs, 3CRs out of 20 patients.
Neratinib plus Kadcyla (T-DM1)
HER2-positive metastatic breast cancer

Latest News

  1. See what the IHS Markit Score report has to say about Puma Biotechnology Inc.
  2. Investors Are Right to Worry About Puma Biotechnology
  3. How Are Expenses Trending for Puma Biotechnology in 2019?
  4. Analysts Expect Puma Biotechnology to Become Profitable in 2020
  5. Puma Biotechnology Reduced Guidance for NERLYNX Sales
  6. What Analysts Are Recommending for Puma Biotechnology
  7. Jim Cramer Gives His Opinion On Becton Dickinson, Fox, Puma Biotech And More
  8. Biotech Hammered On 'Shockingly Poor' Report For Breast Cancer Drug
  9. Here's Why Puma Biotechnology Fell as Much as 40.7% Today
  10. Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales
  11. Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report
  12. Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints
  13. Puma Biotechnology Inc (PBYI) Q1 2019 Earnings Call Transcript
  14. Edited Transcript of PBYI earnings conference call or presentation 9-May-19 8:30pm GMT
  15. Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
  16. Puma Biotech: 1Q Earnings Snapshot
  17. Puma Bio down 33% as more patients forgoing treatment with its cancer drug
  18. Puma Biotechnology Reports First Quarter 2019 Financial Results
  19. Here's Why Puma Biotechnology Fell 17.2% in April
  20. Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019